Regulators See Trend To Reduced Clinical Data Requirements For Biosimilars
This article was originally published in SRA
The amount of clinical trial data needed to support a biosimilar drug application is declining as more experience is gained with biosimilar use and more use is made of increasingly sensitive analytical tools. Moreover, the concept of extrapolation of indications is gaining more credence, and the idea of immunogenicity as a particular problem with biosimilars seems to be losing traction.
Register for our free email digests: